<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256736</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-TCZ302</org_study_id>
    <nct_id>NCT01256736</nct_id>
  </id_info>
  <brief_title>To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate 1 year extension study of the efficacy and the
      safety during treatment tocilizumab in patients completing treatment CWP-TCZ301 study with
      moderate to severe active RA and an inadequate response to current DMARD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety results</measure>
    <time_frame>48weeks</time_frame>
    <description>All AE/ADR during study
Physical examination including vital signs and ECG
Clinical laboratory results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ACR20, ACR50 and ACR70 responses at post therapy</measure>
    <time_frame>48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintain with ACR20, ACR50 and ACR 70 responses at post therapy</measure>
    <time_frame>48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of individual parameter in ACR core set</measure>
    <time_frame>48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of individual parameter in DAS28</measure>
    <time_frame>48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of individual parameter in Rheumatoid factor</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab 8mg/kg + DMARDs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks</description>
    <arm_group_label>Tocilizumab 8mg/kg + DMARDs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMARDs</intervention_name>
    <description>DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)</description>
    <arm_group_label>Tocilizumab 8mg/kg + DMARDs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients Who have been satisfied the in/exclusion criteria of CWP-TCZ301

          -  Patients who have been withdrawn after receiving escape therapy or completed treatment
             during 24weeks in CWP-TCZ301 study

          -  Patients who able to enroll in this study within 12 weeks after last infusion of
             CWP-TCZ301

          -  Willing to give written informed consent

        Exclusion Criteria:

          -  History of severe allergic or anaphylactic reactions to Investigational product in
             CWP-TCZ301 study

          -  ALT or AST &gt; ULNⅹ2.5

          -  Platelet count &lt; 100ⅹ103/ μL

          -  WBC &lt; 3,000/mm3

          -  Absolute neutrophil count &lt; 1,000/mm3

          -  Absolute lymphocyte count &lt; 500/mm3

          -  Total bilirubin &gt; ULNⅹ2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National Univ. Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

